Atara Biotherapeutics (ATRA) Equity Average (2022 - 2025)
Atara Biotherapeutics (ATRA) has disclosed Equity Average for 4 consecutive years, with -$35.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average rose 64.41% year-over-year to -$35.8 million, compared with a TTM value of -$35.8 million through Sep 2025, up 64.41%, and an annual FY2024 reading of -$98.3 million, down 816.97% over the prior year.
- Equity Average was -$35.8 million for Q3 2025 at Atara Biotherapeutics, up from -$45.1 million in the prior quarter.
- Across five years, Equity Average topped out at $240.9 million in Q2 2022 and bottomed at -$104.6 million in Q2 2024.
- Average Equity Average over 4 years is $7.2 million, with a median of -$40.4 million recorded in 2025.
- The sharpest move saw Equity Average crashed 388.86% in 2024, then skyrocketed 64.41% in 2025.
- Year by year, Equity Average stood at $156.9 million in 2022, then crashed by 147.83% to -$75.0 million in 2023, then decreased by 25.16% to -$93.9 million in 2024, then soared by 61.84% to -$35.8 million in 2025.
- Business Quant data shows Equity Average for ATRA at -$35.8 million in Q3 2025, -$45.1 million in Q2 2025, and -$76.2 million in Q1 2025.